Avalo Therapeutics, Inc. · NASDAQ:AVTX

Sullivan Christopher Ryan sold 72,725 Avalo Therapeutics, Inc. shares (Form 4)

Traded Aug 17 to Aug 18, 2026 · Filed Aug 19, 2026

From Aug 17 to Aug 18, 2026, Sullivan Christopher Ryan (Chief Financial Officer) sold 72,725 Avalo Therapeutics, Inc. shares at an average US$19.94 for US$1.45M under a trading plan, leaving 39,900 shares. Filed Aug 19, 2026 (Form 4).

Sold
72,725 shares
Price
US$19.94 average (US$19.85 to US$20.05)
Value
US$1.45M
Holding after
39,900 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Aug 17, 2026Common StockOption exercise37,945US$9.8878,718Direct
Aug 17, 2026Common StockOption exercise2,876US$9.8881,594Direct
Aug 17, 2026Common StockSale37,945US$19.8543,649Direct
Aug 17, 2026Common StockSale3,749US$19.9439,900Direct
Aug 18, 2026Common StockOption exercise31,031US$9.8870,931Direct
Aug 18, 2026Common StockSale31,031US$20.0539,900Direct

Source

View original at SEC

Related